ImmuneOnco’s IMM27M，an ADCC-enhanced CTLA-4 antibody completed the first patient enrollment and dosing
On June 15, 2022, Immuneonco Biopharmaceuticals(Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that our newly developed ADCC-enhanced CTLA-4 antibody (IMM27M) completed the first patient enrollment and first dosing. The administration and the infusion process was smooth.
The target CTLA-4 is the first clinically validated immune checkpoint and the first antibody drug (ipilimumab) approved for marketing in 2011. The price of one dose in the first prescription issued in China is￥28,000.
IMM27M is an IgG1 antibody against CTLA-4. It has been genetically engineered to enhance ADCC activity. Comparing to the similar drug Ipilimumab, its efficacy in animals is much better at the same dosage (see the fig.). And IMM27M can remove the tumor completely at as low as 0.3 mg/kg.
Dr. Tian, Wenzhi, the founder, chairman and CEO of ImmuneOnco, said:
"We are very pleased that our next-generation CTLA-4 antibody project, IMM27M, completed the first patient enrollment and dosing. Multiple repeatable in vivo studies have demonstrated that IMM27M has strong anti-tumor activity and can be combined with various drugs in the company's pipeline. The combination therapy of CTLA-4 with PD1/PD-L1 has been proven to have clear clinical synergy, and indeed BMS' ipilimumab combined with Opdivo has been approved by the FDA for multiple indications including melanoma, colorectal cancer, renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer.We believe that IMM27M have great value for clinical development.”
"We will continue to advance the research of the IMM27M project to bring good news to cancer patients.’’
IMM27M is a new generation of CTLA-4 antibody independently developed by ImmuneOnco. It's with enhanced ADCC activity through genetic engineering technology and can completely eliminate Treg cells in the tumor microenvironment. IMM27M has strong efficacy as a single agent, or can combine with a variety of drugs in the company's product pipeline, such as IMM01 (CD47), IMM2510 (VEGF/PD-L1), IMM2902 (CD47/HER2) or IMM2520 (CD47/PD-L1).